The company's lead product candidate is vilobelimab, a first-in-class anti-C5a monoclonal antibody, which completed Phase III clinical trials for hidradenitis suppurativa and is in Phase II development for anti-neutrophil cytoplasm antibody associated vasculitis and other indications. Multiple near-term catalysts are anticipated including interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum with recommendation expected end of May to early June, and topline data for INF904 Phase 2a trial expected in summer 2025.
Cyborg Score Rationale
InflaRx has a strong technology platform and multiple clinical programs advancing through key milestones, but remains clinical-stage with no approved commercial products beyond EUA for COVID-19. Financial runway appears adequate with €65.7 million in cash, but execution risk remains high.
Top Insights
Lead candidate vilobelimab completed Phase 3 trial in hidradenitis suppurativa with multiple other indications in Phase 2 development
Dual pipeline approach: intravenous vilobelimab and oral INF904 targeting C5a pathway across multiple inflammatory and autoimmune diseases
Emergency Use Authorization for COVID-19 treatment (Gohibic) in place since April 2023 but limited to pandemic duration
Multiple anticipated milestones in 2025-2026 including PG Phase 3 interim analysis and INF904 Phase 2a data readouts could substantially de-risk program
Named Competitors
C5a Inhibitors — Collaborate and compete in complement inhibition space
General Anti-inflammatory Therapeutics — Broad competition in autoimmune and inflammatory disease markets
Recent Developments
(May 2025) Q1 2025 results: €65.7 million in cash after underwritten public offering; confirmed near-term catalysts
(May 2025) Interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum scheduled for end of May to early June 2025
(May 2025) Topline data for INF904 Phase 2a trials in CSU and HS expected summer 2025
Open the full interactive InflaRx N.V. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.